Sense Diagnostics and Inflect Health Collaborate to Improve Outcomes for Stroke and Brain Injury Patients

We’re delivering access to our network of world-class clinical experts

At Inflect Health, we take great pride in our ability to connect early-stage healthcare innovators with the capital and expertise they require to bring their concepts to life. As physicians and healthcare strategists working on the industry’s frontlines, we see firsthand just how devastating some medical conditions can be and are deeply passionate about saving lives. Which is why, when we first heard of a small but dynamic team doing some challenging and incredibly valuable work with stroke and brain injury patients, our interest was immediately piqued.

Based out of Cincinnati, Ohio, Sense Neuro Diagnostics is a medical technology company focused on improving outcomes for stroke and brain injury patients through technology innovations that enable faster detection and more effective triage. Sense is developing non-invasive technology to enable continuous, real-time brain injury monitoring as well as rapid detection of traumatic brain injury and important stroke subtypes — ischemic stroke with large vessel occlusion, ischemic stroke without large vessel occlusion, and intracerebral hemorrhage.

While there are a number of companies in the healthcare space focused on addressing the needs of stroke and brain injury patients, it’s Sense’s approach to the science that’s unique. Sense has developed novel technology to meet a need identified by its medical co-founders, who are specialists in emergency medicine, neurology and neurocritical care. When treating stroke and brain injury, time to proper care is critical; however there is currently no objective way to detect brain injury and stroke subtype in a field environment, or to non-invasively and continuously monitor brain injury for expanded hemorrhage in the hospital. Sense is developing non-invasive brain scanners: headsets equipped with antennae that transmit and receive a low-power tailored radio frequency (RF) pulse across the brain. This signal is scattered and absorbed differently by normal brain tissue, intracranial hemorrhage, and tissue from ischemic injury such as stroke.

What’s more, Sense has initiated a multicenter pivotal trial to evaluate the safety and efficacy of its non-invasive brain scanner to monitor intracranial hemorrhage in an acute hospital setting. The study follows positive in vitro and in vivo proof of concept studies and a successful first-in-human feasibility study. Up to 400 patients will be enrolled at sites across the US, Canada and India.

As for Inflect Health’s involvement, we’re excited to support the development of Sense products and markets with the help of our access to a network of 3,000 physicians, 2,000 advanced providers, 1,500 scribes and more than 300 hospitals. We’ll also serve as a key opinion leader for market development, commercial awareness and go to market strategy.

“Through innovation, Sense Neuro Diagnostics is addressing a critical need identified by its medical co-founders and well understood by physicians who practice emergency medicine, neurology and neurocritical care,” said Inflect Health President and Vituity Chief Operations and Innovation Officers Andrew Smith. “We are pleased to partner with Sense on a range of possible market applications for this promising technology.”

For more information about Sense Neuro be sure to visit their website at https://senseneuro.com or follow them on Twitter and LinkedIn.